Actively Recruiting
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism: a Prospective FDG PET Study
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-08-22
56
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of FDG PET scans to study brain glucose metabolism in patients with confirmed autoimmune encephalitis. This condition is difficult to diagnose early, which is critical for better neurological outcomes. The study focuses on 56 patients diagnosed based on established criteria from 2016 and 2021, aiming to assess the diagnostic value of FDG PET performed during the acute phase before or shortly after starting immunomodulating treatment. Participants will undergo an initial FDG PET scan at the acute phase, either before immunomodulating treatment begins or within 10 days after starting treatment. A follow-up FDG PET scan will be done three months after treatment initiation to analyze changes over time. This prospective study investigates how FDG PET compares to standard imaging like MRI in detecting autoimmune encephalitis. During the study, participants will have brain FDG PET scans at the specified times, with evaluations of brain glucose metabolism as the main outcome. Researchers will monitor the initial scan results and follow-up scans to understand disease progression and treatment impact. The total study participation involves scans before and three months after treatment, along with assessments to confirm diagnosis and eligibility.
CONDITIONS
Brief Title
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Newly diagnosed autoimmune encephalitis based on at least one of the following: definite limbic autoimmune encephalitis per 2016 Graus criteria; possible autoimmune encephalitis with typical autoantibody detected in serum or CSF; probable or certain paraneoplastic neurological syndrome per 2021 criteria (excluding peripheral neurological syndromes)
- Less than 6 months since first neurological symptoms related to autoimmune encephalitis
- Affiliated or entitled to a social security system (except AME)
- Provided free, written, and informed consent (patient, legal representative, or close relative)
You will not qualify if you...
- History of brain tumor, head trauma, infarction, or cerebral hematoma likely to alter brain carbohydrate metabolism on PET
- Immunotherapy for autoimmune encephalitis started more than 10 days ago
- Pregnant or breastfeeding women
- Ventilated intubated patients
- Absolute contraindications to MRI (e.g., pacemaker, cochlear implant)
- Cognitive disorders preventing cooperation with PET scan
- Painful or agitated patients unable to remain still in supine position for 30 minutes
- Persons deprived of liberty or under guardianship or curatorship
- Participation in other interventional research involving radiopharmaceutical injections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 10 days after screening
Participants undergo an initial brain FDG PET scan performed in the acute phase before immunomodulating treatment or within 10 days of treatment initiation to evaluate brain glucose metabolism.
1 visit (in-person)
Duration - 3 months after treatment initiation
Participants receive a follow-up brain FDG PET scan approximately 3 months after treatment initiation to assess changes in brain glucose metabolism.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Hospital Pitie Salpetriere
Paris, France, 75013
Actively Recruiting
Research Team
A
Aurélie Kas, Pr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here